Josephine Lilla, MD
Family Medicine · Kokomo, INNPI 1184727968
Payments from drug & device makers
Across 568 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$970
- AbbVie$956
- Bayer$727
- Pfizer$596
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,02999%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,245 |
| Novo Nordisk | 89 | $1,055 |
| Lilly USA, LLC | 54 | $970 |
| AbbVie(2 entities) | 79 | $956 |
| Bayer | 51 | $727 |
| Pfizer | 33 | $596 |
| GSK | 35 | $433 |
| Astellas Pharma US Inc | 16 | $342 |
| Amgen | 18 | $333 |
| Boehringer Ingelheim | 19 | $312 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $218 |
| Otsuka America Pharmaceutical, Inc. | 10 | $210 |
| Axsome Therapeutics, Inc. | 7 | $178 |
| Edwards Lifesciences | 2 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $157 |
| Abbott | 8 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $110 |
| Exact Sciences | 5 | $97 |
| Lundbeck LLC | 5 | $89 |
| Dexcom, Inc. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Merck | 3 | $73 |
| Ironwood Pharmaceuticals, Inc | 5 | $70 |
| Phathom Pharmaceuticals, Inc. | 6 | $63 |
| Sanofi Pasteur Inc. | 2 | $51 |
| Amarin Pharma, Inc. | 3 | $49 |
| Novartis | 3 | $46 |
| Johnson & Johnson | 3 | $44 |
| Mylan Specialty L.p. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,090 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $200,092 |
| JardianceEmpagliflozin | 76 | $75,580 |
| TrulicityDulaglutide | 37 | $60,486 |
| JanuviaSitagliptin Phosphate | 56 | $54,279 |
| MyrbetriqMirabegron | 78 | $50,468 |
| EliquisApixaban | 53 | $49,329 |
| MounjaroTirzepatide | 40 | $47,478 |
| FarxigaDapagliflozin Propanediol | 31 | $40,176 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $36,224 |
| LinzessLinaclotide | 40 | $27,070 |
| Aripiprazole | 19 | $21,918 |
| XareltoRivaroxaban | 13 | $21,568 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $20,040 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 33 | $19,397 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 58 | $18,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,055 | $200,092154 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $970 | $107,96477 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $312 | $94,976109 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta | $433 | $79,778147 claims |
| PfizerEliquis, Abrysvo, Premarin | $596 | $73,564122 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $342 | $55,93389 claims |
| MerckJanuvia | $73 | $54,27956 claims |
| AstraZenecaFarxiga | $1,245 | $40,17631 claims |
| AbbVieLinzess | $956 | $27,07040 claims |
| Johnson & JohnsonXarelto | $44 | $21,56813 claims |
| BayerKerendia | $727 | $7,70012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $157 | $4,90713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Kokomo
- Victoria MoyerKokomo$188K
- Sheryar SarwarKokomo$22K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.